Reaching the Frail Elderly for the Management of Atrial Fibrillation (REAFEL)

April 17, 2022 updated by: Helena DOMINGUEZ, University Hospital Bispebjerg and Frederiksberg

The overall objective of the project is to develop a collaboration model between the patient, the patient's General Practitioner (GP) and the cardiologist at the hospital in a seamless collaborative model dubbed the "Cardio-relay model".

The specific purpose of the pilot project is to ease performing heart rhythm monitoring with focus on diagnosis and evaluation of atrial fibrillation (AF), for patients who have difficulties to attend repeated visits to the hospital-based outpatient clinic.

With available eHealth technologies the cardiologist can access data gathered at the patient's side to provide support to the GP for selecting patients with need for heart rhythm monitoring, plan further evaluations and guide therapeutic decisions. These patients can thereby receive support that without the burden of attending physical meetings at the cardiologist office. The investigators evaluate if the cardio-relay model allows to complete evaluation of frail patients compared to usual care and if patients experience are sufficiently confident accessing the cardiologist through the cardio-relay model.

Study Overview

Status

Completed

Conditions

Detailed Description

Hypothesis Our overall hypothesis is, that using the cardio-relay model it is possible to provide adequate treatment to frail patients that have difficulties to attend repeated visits at the hospital-based cardiologist office.

Our concrete hypothesis is that a larger number of frail patients reaches adequate treatment with the cardio-relay model compared with conventional treatment and the patient remains confident with the distant support by the cardiologist.

METHODS This is a pragmatic clinical trial that uses mixed methods in different stages of the project to test this hypothesis. Observational during the initial feasibility period, an open-label cluster-randomization trial and an iterative implementation period.

Phase 1 - Feasibility During this phase, a single GP clinic is used to establish the elements that permit to establish the cardio-relay model. Hence, a field study is required to initiate the study.

Subsequently, the first of such elements in the cardio-relay model is a text exchange initiated by the GP addressing a request to the cardiologist to assess the need for heart rhythm monitoring. This is a replacement of usual referral when the cardiologist is expected to plan an appointment for the patient In the cardiology outpatient clinic or reject the referral. In the cardio-relay model, through a text exchange. The GP may require further examinations and add eventual results available in the hospital electronic records from previous contacts. The GP, the cardiologist and the patient (welcoming help from relatives and carers) can then agree on need for heart rhythm monitoring. The GP has available compact Holter sensors, C3+, from Cortrium ApS and can immediately initiate recordings at their office or at the patient's home. The duration of the recording is 24 hours as standard, but can agreed to prolong or repeat between the GP, the cardiologist and the patient. C3+ has memory for continuous electrocardiogram recording and built-in accelerometer, for up to three weeks and battery capacity for one weeks. The finalized recordings can be uploaded to the cloud by the GP and the cardiologist provides the GP with a result of the recording and a proposal for treatment according to the findings or further evaluation, which continuous the dialogue across the sectors

Phase 2 - Cluster randomization trial The terms of patient confidentiality are identic to those for usual care as patient management aims at best clinical practice according to local guidelines and data are recorded in the existing medical records. Hence, analysis of the observations gathered during Phase 1 correspond to those of a quality control project, with no requirement to gather specific informed consent for this part. The project has been accepted by the Ethics Committee of the Capital region (H-18052892) and published in clinicaltrials.gov for extending usual clinical management with questionnaires and structured interviews with patients to assess the satisfaction of the novel management with the cardio-relay model, with emphasis on the patient's perspective.

To allow comparison of the novel collaborative model cardio-relay with usual care, there will be conducted a cluster-randomization trial. Firstly, other GP clinics will be recruited by personal visit at the clinics where the cardio-relay model is briefly introduced. GP clinics will be invited to participate from different regions, that is, Bispebjerg-Frederiksberg municipality and Holbæk municipality, four from each municipality. That is eight GP clinics in total. During a subsequent workshop, the participant GP clinics will be invited to a workshop where they will be informed on the project and discuss best pathways to achieve the goals of the project, based on the principle of the project, adapted to the local GP characteristics. Collaboration agreements will be signed with the participant GP clinics they will be allocated to cluster by Region and randomized to intervention or no intervention. All sites send an initial message to the clinics to discuss the wish of Holter monitoring. In the control group, the initial requirement for Holter monitoring will be handled according to usual care. In the intervention group, GP will receive advise to start a C3+ Holter or not, eventually after a dialogue to qualify indication for Holter monitoring, and receive a treatment and further evaluation proposal, as described in the feasibility phase.

Measurements of efficacy will be initiated after the first two patients are managed in each site, both according to the control group and according to the intervention group. That is, 16 patients in total in the run-in period. It is planned to evaluate the results of Phase 2 when the first 50 patients are included and followed for six months (that is 16 patients run-in and 34 randomized). Measurements for the 34 patients managed according to randomization. This is an estimate based on an expected optimization of the following primary endpoint:

• Completion of evaluation for definite or roll-out diagnosis within six weeks in 90% of patients included in the intervention arm compared to 70% within six weeks These estimates are based on the time from referral to clinical visit for treatment decision or completed rule-out evaluation time in current settings on 120 patients referred to Bispebjerg-Frederiksberg hospital for evaluation for atrial fibrillation in the period January-June 2019 (mean 58 days, CI 11.27). This will be recalculated when the results of Phase 1 are available.

Questionnaires and patient interviews Questionnaires include validated assessment tools: Euro Quality of Life-5 Domain (EQ-5D) READY concept-based, psychometrically sound, validated instrument, the Readiness and Enablement Index for Health Technology (READHY), based on the concept of eHealth literacy supplemented with relevant scales from other instruments assessing aspects of self-management and social support: the eHealth Literacy Questionnaire (eHLQ) the Health Education Impact Questionnaire (heiQ) and the Health Literacy Questionnaire (HLQ).

Measurements

For questionnaires:

All instruments are based on conceptual dimensions and are rated on a Likert-type scale from 1 (strongly disagree) to 4 (strongly agree). The overall svore of each dimension is calculated as the mean of the items constituting the dimension.

For interviews:

All transcribed interviews will be were coded and categorized inductively using manifest qualitative content analysis, Qualitative data from the patient interviews will be reported in accordance with COREQ guidelines. Recruitment of patients for interviews will be prospective, with a "purposive approach. Every patient who agrees to take part in the project will be classified as "frail" or "not frail" pursuant to the pre-defined criteria (Table 1). Continuous comparison methods will be used to identify the population which could benefit from the cardio-relay model.

Table 1. "Frail elderly" are aged ≥ 65 years and have at least one of the following impairments:

  • Transportation: Need for help to get to hospital outpatient departments
  • Personal care: Need for help in personal hygiene
  • Walking impairment: Reduced ability to walk (takes more than 5 sec. for the patient to walk 5 metres)
  • Weight loss: Unintentional weight loss within the past year
  • Cognitive difficulties: dementia, memory problems, aphasia, etc.
  • Social problems: due to alcohol abuse or other abuse, ethnic background, language, etc.

Phase 3 - Iterative adjustment It is expectable that, after initial use of the cardio-relay model in REAFEL in the prior phases, there will be unforeseen improvement possibilities that can be adjusted in an iterative manner in the different settings for each participating sites. After a 6 months period it is expected to draw a generalizable guide for managing patients with the cardio-relay model.

Reporting results of the entire trial will follow TIDieR checklist.

Study Type

Observational

Enrollment (Actual)

344

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Frederiksberg, Denmark, 2000
        • Cardiology department Y, Bispebjerg-Frederiksberg Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients referred from primary care to assess atrial fibrillation diagnosis and burden "Frail elderly" are aged ≥ 65 years and have at least one of the following impairments:

  • Transportation: Need for help to get to hospital outpatient departments
  • Personal care: Need for help in personal hygiene
  • Walking impairment: Reduced ability to walk (takes more than 5 sec. for the patient to walk 5 metres)
  • Weight loss: Unintentional weight loss within the past year
  • Cognitive difficulties: dementia, memory problems, aphasia, etc.
  • Social problems: due to alcohol abuse or other abuse, ethnic background, language, etc.

Description

Inclusion Criteria:

  • "Frail elderly" are aged ≥ 65 years
  • Non-frail adults (> 18 years old)

Exclusion Criteria:

  • Not willingness to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
cardio-relay

"Cardio-relay" is a novel collaboration model between hospital-based specialists and primary care, to provide high-quality care to frail patients, relieving their burden to attend multiple hospital specialist visits.

Using telemedicine, it is possible to make measurements where the patient is (at the family clinic at the patient's home). Data are available for all the involved. That is, primary the patient, the relatives and caregivers that the patient wishes help from and health professionals from the family clinics and the hospital. Thereby, the hospital-based specialist supports the family clinic with expert knowledge, the need for attending the hospital facilities reduced to focus on what is strictly needed as specialized provider. Ultimately, the patient can be reached for high-quality care, relieving the patient's burden to attend multiple hospital specialist visits.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to diagnosis conclusion
Time Frame: six months follow-up
Completion of evaluation for definite or rule-out diagnosis within six weeks in 90% of patients included in the intervention arm compared to 70% within six weeks
six months follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification of population that benefits with the cardio-relay model
Time Frame: six months follow-up
patient satisfaction measured with focused interviews
six months follow-up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of referrals
Time Frame: six months follow-up
Explorative analysis on number of referrals to the cardiology outpatient clinic
six months follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 1, 2020

Primary Completion (ACTUAL)

March 31, 2022

Study Completion (ACTUAL)

March 31, 2022

Study Registration Dates

First Submitted

November 11, 2019

First Submitted That Met QC Criteria

November 11, 2019

First Posted (ACTUAL)

November 14, 2019

Study Record Updates

Last Update Posted (ACTUAL)

April 19, 2022

Last Update Submitted That Met QC Criteria

April 17, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • H-18052892

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

3
Subscribe